10-Q: Ernexa Therapeutics Reports Q1 2025 Results, Highlights Going Concern Uncertainty and New Financing

Ernexa Therapeutics reports a net loss of $8.2 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern, while also announcing a new securities purchase agreement.

Summary

• Ernexa Therapeutics Inc. is a preclinical-stage synthetic allogeneic iMSC therapy company.
• The company's Q1 2025 net loss was $8.2 million, which includes a $5.3 million non-cash expense related to a forward sales contract.
• The company used $2.1 million in operating activities during the quarter.
• As of March 31, 2025, Ernexa had a cash balance of approximately $1.9 million and an accumulated deficit of approximately $239.7 million.
• Management has concluded that there is substantial doubt regarding the company's ability to continue as a going concern.
• The company will need to raise additional capital to fund operations for the next twelve months.
• On March 31, 2025, Ernexa entered into a securities purchase agreement (SPA) for approximately $7.3 million through a private placement of common stock and pre-funded warrants.
• The first closing of the SPA occurred on April 2, 2025, generating $1.1 million in gross proceeds.
• The second closing, expected to generate $6.2 million, is contingent upon shareholder approval at the annual meeting on June 2, 2025.
• The company plans to use the proceeds from the financing for general working capital purposes and to pay off promissory notes.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's going concern warning, significant net loss, and need for additional capital. While the recent financing provides some relief, the overall financial situation is precarious.

Positives

• The company secured $1.1 million in gross proceeds from the first closing of a private placement on April 2, 2025.
• A second closing of the private placement is expected to generate an additional $6.2 million, pending shareholder approval.
• The company is developing ERNA-101 in platinum-resistant, ovarian cancer.
• The company is investigating anti-inflammatory cytokine (e.g. IL-10)-secreting iMSCs in inflammatory/auto-immune disorders like Rheumatoid arthritis, which we refer to as ERNA-102.
• The company expects to complete IND enabling studies and IND submission by 2026 and to subsequently enter a Phase I investigator sponsored clinical trial in the second half of 2026.
• General and administrative expenses decreased by approximately $2.9 million for the three months ended March 31, 2025 compared to the three months ended March 31, 2024 primarily due to reduced rent expense due to a sublease we terminated in August 2024, decreases in professional fees related to legal services and consultants, and a reduction in payroll related expenses.

Negatives

• The company reported a net loss of $8.2 million for Q1 2025.
• The company has an accumulated deficit of approximately $239.7 million as of March 31, 2025.
• Management has expressed substantial doubt about the company's ability to continue as a going concern.
• The company's auditor has raised concerns about the company's ability to continue as a going concern.
• The company's cash balance as of March 31, 2025, was approximately $1.9 million.
• The company will need to raise additional capital to fund operations for the next twelve months.
• The company's common stock is listed on The Nasdaq Capital Market and the company received notice from Nasdaq that it no longer met the Bid Price Rule and were provided until June 30, 2025 to regain compliance with the Bid Price Rule.
• The company received notice from Nasdaq informing us that we no longer met the MVLS Rule and were provided until July 7, 2025 to regain compliance with the MLVS Rule.

Risks

• The company's ability to continue as a going concern is uncertain.
• The company may not be able to raise additional capital when needed, on acceptable terms, or at all.
• Failure to meet Nasdaq continued listing requirements could result in delisting of the company's common stock.
• The company's stock price could be negatively impacted by the company's financial condition and the uncertainty surrounding its ability to continue as a going concern.
• The company's research and development efforts may not be successful.
• The company may face competition from other companies in the biotechnology industry.
• The company's products may not be approved by regulatory agencies.
• The company may be subject to legal proceedings.
• The company's intellectual property may not be adequately protected.
• The company's success depends on its ability to attract and retain qualified personnel.

Future Outlook

The company plans to use the proceeds from the recent financing for general working capital purposes and to pay off promissory notes. The company expects to complete IND enabling studies and IND submission by 2026 and to subsequently enter a Phase I investigator sponsored clinical trial in the second half of 2026. The company will need to raise additional capital to fund operations for the next twelve months.

Management Comments

• Management has concluded that there is substantial doubt regarding the company's ability to continue as a going concern.
• We will continue to focus on finding operational efficiencies that result in cost savings.

Industry Context

Ernexa is operating in the competitive preclinical-stage biotechnology industry, focusing on allogeneic iMSC therapies. The company's focus on solid tumors and autoimmune diseases aligns with significant unmet medical needs, but the company faces challenges common to early-stage biotech companies, including securing funding, achieving clinical milestones, and navigating regulatory hurdles.

Comparison to Industry Standards

• Given Ernexa's preclinical stage, direct comparison to revenue-generating industry leaders is not applicable.
• However, similar companies like Lineage Cell Therapeutics and Fate Therapeutics, which are also focused on allogeneic cell therapies, serve as benchmarks for clinical development timelines and fundraising strategies.
• Lineage Cell Therapeutics, for example, has faced similar challenges in securing funding and advancing clinical programs.
• Fate Therapeutics, while further along in clinical development, demonstrates the potential upside of successful allogeneic cell therapies.
• Ernexa's cash position and burn rate should be compared to those of peer companies at similar stages of development to assess its financial runway.
• The $7.3 million capital raise is relatively small compared to financings by more advanced companies, highlighting the need for further capital infusions to support clinical development.

Legal Proceedings

• The company is involved in litigation and arbitrations from time to time in the ordinary course of business.
• On April 22, 2025, Counterclaim Defendants and Westman reached a confidential settlement with an effective date of April 30, 2025.

Related Party Transactions

• Charles Cherington, who owns approximately 33% of the company's outstanding common stock and previously served on the board, participated in the September 2024 and March 2025 financings under the same terms as other investors.
• The company received $2.3 million in promissory notes from Charles Cherington in March 2025.

Stakeholder Impact

• Shareholders face significant risk due to the company's going concern uncertainty and potential delisting from Nasdaq.
• Employees may be affected by potential cost-cutting measures or restructuring.
• The company's ability to advance its therapeutic programs and potentially benefit patients is contingent on securing additional funding.
• Creditors face increased risk due to the company's financial instability.

Next Steps

• Obtain shareholder approval for the second closing of the securities purchase agreement at the annual meeting on June 2, 2025.
• Secure additional funding to support operations for the next twelve months.
• Regain compliance with Nasdaq listing requirements.
• Advance ERNA-101 and ERNA-102 through preclinical development.
• Complete IND enabling studies and IND submission by 2026 and to subsequently enter a Phase I investigator sponsored clinical trial in the second half of 2026.

Key Dates

Keywords

Ernexa Therapeutics, iMSC therapy, Financial Results, Going Concern, Capital Raise, Q1 2025, Biotechnology, Pharmaceuticals, Clinical Trials, ERNA-101, ERNA-102